RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Emoksipin

Product
Developers: Enzyme Firm
Branches: Pharmaceuticals, medicine, healthcare,  Manufacturers of medical devices

History

2022: Roszdravnadzor recalls Emoxipin eye drops due to glass fragment in the bottle

In April 2022, the Federal Health Care Supervision Service (Roszdravnadzor) announced the recall of Emoxipin eye drops (methylethylpyridinol) manufactured by Enzyme Firm LLC (Russia). These measures were taken after glass fragments were found in one of the vials of the ophthalmic drug.

The preparation "Emoxipin, eye drops 1% 5 ml, vials, cardboard packs/complete with a drip lid" of the 270921 series was withdrawn from circulation. If this series is found in its assortment, pharmacies must provide information to the territorial body of Roszdravnadzor confirming the return of the drug to suppliers or manufacturer.

Roszdravnadzor recalls eye drops "Emoxipin"

Emoxipine is used to treat the following diseases:

  • corneal burns;
  • keratitis (inflammation of the cornea);

hemorrhages to the sclera, to the anterior chamber of the eye;

  • thrombosis of the central vein and branches of the retina;

diabetic retinopathy;

  • complications of myopia.

According to the manufacturer, when used, microcirculation is improved, the oxidation of lipids of biological membranes is blocked. In a situation where the visual organ is in extreme conditions, suffers from a lack of oxygen, the drug contributes to the optimization of bioenergy processes. The drug protects the retina from damage by intense light, improves the microcirculation of the eyeball, and promotes the resorption of hemorrhages inside the eye.


This is not the first time that foreign objects have been detected in packages of medicines. In December 2021, glass fragments were found in the packaging of the Bifilis (VIGEL) drug of the same manufacturer. In addition, in June 2021, due to glass fragments in ampoules, the Sulzoncef antibiotic series was withdrawn from circulation, and in September 2020, Roszdravnadzor suspended the implementation of the Pancreatin-LekT enzyme drug series due to the fact that an insect was in one of the blister cells instead of a tablet.[1]